BeOne Medicines (ONC) Short term Debt (2015 - 2026)

BeOne Medicines (ONC) has 11 years of Short term Debt data on file, last reported at $116.1 million in Q1 2026.

• Quarterly Short term Debt fell 84.79% year-over-year to $116.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.1 million (down 84.79% YoY) and the FY2025 annual result came in at $57.3 million, down 93.27% from the prior year.
• Short term Debt grew to $116.1 million in Q1 2026 per ONC's latest filing, from $57.3 million in the prior quarter.
• Across five years, Short term Debt topped out at $863.8 million in Q3 2024 and bottomed at $57.3 million in Q4 2025.
• The 5-year median for Short term Debt is $564.8 million (2022), against an average of $556.4 million.
• The widest annual swing landed in 2024, when Short term Debt surged 193.45%; it then tumbled 93.27% in 2025.
• Tracing ONC's Short term Debt over 5 years: stood at $441.3 million in 2022, then soared by 55.99% to $688.4 million in 2023, then grew by 23.7% to $851.5 million in 2024, then plunged by 93.27% to $57.3 million in 2025, then soared by 102.71% to $116.1 million in 2026.
• Per Business Quant, the three latest ONC Short term Debt figures stand at $116.1 million (Q1 2026), $57.3 million (Q4 2025), and $813.3 million (Q3 2025).

Peer Comparison